Evidence map›Paper›PMID 36694080›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Lactobacillus for ribosome peptide editing cancer.

Shousong Yue, Qiuxia He, Jean-François Picimbon

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Shousong YueBiotechnology Research Center, Shandong Academy of Agricultural Sciences, 202 Gongye North Road, Jinan, 250100, Shandong, China.
Qiuxia HeScience and Technology Service Platform of Shandong Academy of Sciences, Shandong Academy of Sciences Foreign Students Pioneer Park, Jinan, 250103, Shandong, China.
Jean-François PicimbonBiotechnology Research Center, Shandong Academy of Agricultural Sciences, 202 Gongye North Road, Jinan, 250100, Shandong, China. jfpicimbon@sdas.org.ORCID http://orcid.org/0000-0002-9440-4772
Qilu University of Technology · CNShandong Academy of Agricultural Sciences · CNShandong Academy of Sciences · CN

Funding

Agricultural Science and Technology Innovation Engineering Program of SAAS CXGC2017A01-1Key Technology Research and Development Program of Shandong 2016GGH3111Ministry of Science and Technology of the People's Republic of China G2022023033LNational Key Technology Research and Development Program 2012BAK17B05Natural Science Foundation of Shandong Province ZR2011CM046Overseas High-level Talent "Hundred People Program" NO.tshw20091015
6 · The paper itself

Abstract

This study reviews newly discovered insect peptide point mutations as new possible cancer research targets. To interpret newly discovered peptide point mutations in insects as new possible cancer research targets, we focused on the numerous peptide changes found in the 'CSP' family on the sex pheromone gland of the female silkworm moth Bombyx mori. We predict that the Bombyx peptide modifications will have a significant effect on cancer CUP (cancers of unknown primary) therapy and that bacterial peptide editing techniques, specifically Lactobacillus combined to CRISPR, will be used to regulate ribosomes and treat cancer in humans.

Indexed as

BombyxNeoplasmsAnimalsFemaleHumansPeptidesRibosomesPeptidesCell multifunctionCell ribosomeCSP modelCUPCysteine insertionGenetic diseaseGlycine insertionMalignant tumorMutational alterationProtein recoding

Identifiers

PMID36694080
PMCPMC9873400
OpenAlexW4317857461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.